

Financial Report

Financial Report	25–62
Consolidated financial statements	26
Consolidated balance sheet as at December 31	26
Consolidated statement of comprehensive income for the year ended December 31	27
Consolidated statement of changes in equity for the year ended December 31	28
Consolidated statement of cash flow for the year ended December 31	29
Notes to the consolidated financial statements	30
Report on the audit of the consolidated financial statements	49
Financial statements BB Biotech AG	53
Balance sheet as at December 31	53
Statement of income for the year ended December 31	54
Notes to the financial statements BB Biotech AG	55
Report on the audit of the financial statements	61

Consolidated balance sheet as at December 31

in CHF 1 000	Notes	2024	2023
Current assets			
Cash and cash equivalents		458	501
Receivables from brokers		–	1 829
Securities	4	2 406 881	2 634 714
Other assets		60	110
		2 407 399	2 637 154
Total assets		2 407 399	2 637 154
Current liabilities			
Short-term borrowings from banks	5	117 500	304 900
Payables to brokers		–	5 436
Other short-term liabilities	6	3 513	3 491
Tax liabilities		94	110
		121 107	313 937
Total liabilities		121 107	313 937
Shareholders' equity			
Share capital	7	11 080	11 080
Treasury shares	7	(39 640)	(36 508)
Retained earnings	7	2 314 852	2 348 645
		2 286 292	2 323 217
Total liabilities and shareholders' equity		2 407 399	2 637 154
Net asset value per share in CHF		41.75	42.35

The notes are an integral part of the consolidated financial statements.

The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on February 18, 2025.

Consolidated statement of comprehensive income for the year ended December 31

in CHF 1 000	Notes	2024	2023
Operating income			
Gains from securities	4	111 548	–
Interest income		84	35
Foreign exchange gains		599	490
Other income		6	5
		112 237	530
Operating expenses			
Losses from securities	4	–	(166 613)
Finance expenses		(4 978)	(5 802)
Administrative expenses	8	(27 359)	(30 083)
Other expenses	9	(3 947)	(4 560)
		(36 284)	(207 058)
Profit/(loss) before tax	12	75 953	(206 528)
Income taxes	10	(54)	(79)
Profit/(loss) for the period		75 899	(206 607)
Total comprehensive profit/(loss) for the period		75 899	(206 607)
Earnings per share in CHF	11	1.38	(3.77)
Diluted earnings per share in CHF	11	1.38	(3.77)

The notes are an integral part of the consolidated financial statements.

Consolidated statement of changes in equity for the year ended December 31

in CHF 1 000	Share capital	Treasury shares	Retained earnings	Total
Balances at January 1, 2023	11 080	(36 508)	2 711 563	2 686 135
Dividend	–	–	(156 311)	(156 311)
Total comprehensive income for the period	–	–	(206 607)	(206 607)
Balances at December 31, 2023	11 080	(36 508)	2 348 645	2 323 217
Balances at January 1, 2024	11 080	(36 508)	2 348 645	2 323 217
Dividend	–	–	(109 692)	(109 692)
Trade with treasury shares	–	(3 132)	–	(3 132)
Total comprehensive income for the period	–	–	75 899	75 899
Balances at December 31, 2024	11 080	(39 640)	2 314 852	2 286 292

The notes are an integral part of the consolidated financial statements.

Consolidated statement of cash flow for the year ended December 31

in CHF 1 000	Notes	2024	2023
Cash flows from operating activities			
Proceeds from sales of securities	4	562 926	449 340
Purchase of securities	4	(227 152)	(195 711)
Interest receipts		84	35
Payments for services		(31 229)	(35 312)
Income taxes paid		(69)	(76)
Total cash flows from operating activities		304 560	218 276
Cash flows from financing activities			
Dividend		(109 692)	(156 311)
Purchase of treasury shares	7	(3 132)	–
Repayment of borrowings	5	(187 400)	(58 100)
Interest payments		(4 978)	(5 802)
Total cash flows from financing activities		(305 202)	(220 213)
Foreign exchange difference		599	490
Change in cash and cash equivalents		(43)	(1 447)
Cash and cash equivalents at the beginning of the period		501	1 948
Cash and cash equivalents at the end of the period		458	501

The notes are an integral part of the consolidated financial statements.

Notes to the consolidated financial statements

1. The Company and its principal activity

BB Biotech AG (the Company) is listed on the SIX Swiss Exchange as well as in the «Prime Standard Segment» of the German Exchange and has its registered office in Schaffhausen/ Switzerland, Schwertstrasse 6. Its principal activity is to invest in companies active in the biotechnology industry for the purpose of capital appreciation. The investments are held through its wholly owned subsidiaries.

Company	Capital in CHF 1 000	Capital and voting interest in %
Biotech Focus N.V., Curaçao	11	100
Biotech Growth N.V., Curaçao	11	100
Biotech Invest N.V., Curaçao	11	100
Biotech Target N.V., Curaçao	11	100

2. Accounting policies

General

The consolidated financial statements of the Company and its subsidiary companies (the Group) have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the IASB, as well as the provisions of the rules of the SIX Swiss Exchange for Investment Companies for the period January 1, 2024, until December 31, 2024. The consolidation is prepared from the financial statements of the Group companies using uniform accounting principles. With the exception of financial assets and liabilities (incl. derivative instruments), which are held at fair value through profit or loss, the financial statements are prepared under the historical cost convention. This requires management to make assumptions and estimates that have an impact on the balance sheet values and items of the income statement in the current financial year. In certain circumstances, the actual values may differ from these estimates.

The following amended standards, valid since January 1, 2024, have been applied in these consolidated financial statements.

- IFRS 16 (amended, effective January 1, 2024) – Lease Liability in a Sale and Leaseback
- IFRS 7/IAS 7 (amended, effective January 1, 2024) – Disclosures Supplier Finance Arrangements
- IAS 1 (amended, effective January 1, 2024) – Classification of Liabilities as Current or Non-current
- IAS 1 (amended, effective January 1, 2024) – Non-current Liabilities with Covenants

The Group assessed the impact of the above-mentioned amended standards. Based on the analysis, the Group concluded that these amended standards have no material impact on the Group's accounting policies and overall results and financial position.

The following new and amended standards were approved, but will only be applicable for the Group prospectively and were not early adopted in these annual consolidated financial statements.

- IAS 21 (amended, effective January 1, 2025) – Lack of Exchangeability
- IFRS 9/IFRS 7 (amended, effective January 1, 2026) – Classification and Measurement of Financial Instruments
- IFRS 18 (effective January 1, 2027) – Presentation and Disclosure in Financial Statements
- IFRS 19 (effective January 1, 2027) – Subsidiaries without Public Accountability: Disclosures

The Group assessed the potential impact of the above-mentioned new and amended standards. Based on the analysis, the Group concludes that these new and amended standards have no material impact on the Group's accounting policies and overall results and financial position.

Basis of consolidation

The consolidated financial statements include the Company and the subsidiary companies which are controlled by it. An investor controls an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Subsidiaries are fully consolidated from the date on which control is transferred to the Company and are deconsolidated from the date that control ceases. The consolidation is performed using the acquisition method. All intercompany transactions and balances with companies included in the consolidation are eliminated. All Group companies have a December 31 year-end.

Foreign currency translation

Based on the economic environment (primary listing, investors, costs and performance measurement) in which the Company and its subsidiaries operate, the consolidated financial statements of the Group are presented in Swiss francs, which is the Company's and its subsidiaries functional currency. Transactions in foreign currencies are converted at exchange rates as at transaction dates. Assets and liabilities in foreign currencies at year-end are translated at rates of exchange prevailing as at the balance sheet date. Exchange differences are reflected in the statement of income. Translation differences on marketable securities held at fair value through profit or loss are reported as part of the gains/(losses) from securities.

The following exchange rates have been used for the preparation of these consolidated financial statements:

Currency	31.12.2024	31.12.2023
USD	0.90740	0.84140
ANG	0.50978	0.47270
EUR	0.94008	0.92887
GBP	1.13560	1.07160

Financial assets

The Group classifies its financial assets in the following categories:

- Financial assets at amortized cost
- Financial assets at fair value through profit or loss

Financial assets at amortized cost

Financial assets at amortized cost are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are generally financial assets held as part of a business model to collect contractual cash flows that are solely payments of interest and principal on the principal outstanding. They are included in current assets, except when they have maturities of greater than twelve months after the balance sheet date. Otherwise they are classified as non-current assets.

Cash and cash equivalents

Cash and cash equivalents comprise current accounts and money at banks which have a maturity of three months or less.

Receivables from brokers

Receivables from brokers result from security transactions and do not bear any interest.

These amounts are recognized initially at fair value and subsequently measured at amortized cost. At each reporting date, the Group shall measure the loss allowance on amounts due from broker at an amount equal to the Lifetime Expected Credit Loss («ECL») if the credit risk has increased significantly since initial recognition. If, at the reporting date, the credit risk has not increased significantly since initial recognition, the Group shall measure the loss allowance at an amount equal to 12-month ECLs. A significant increase in credit risk is defined as any contractual payment which is more than 30 days past due. Any contractual payment which is more than 90 days past due is considered credit impaired. For receivables from brokers which settle within 10 business days the ECL estimate is nil.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss comprise marketable and non-marketable securities which are classified as current assets.

Initially, securities and derivatives are measured at fair value and are subsequently remeasured at market values based on stock exchange prices or generally accepted valuation models that are based on market conditions existing at each balance sheet date, such as Black- Scholes, earnings multiple and discounted cash flow model. Purchases and sales of securities are accounted for at trade date. Realized gains and losses on security trading are recognized in the statement of comprehensive income as gains/losses from securities at the day of the transaction. Changes in fair value of securities are also recognized as gains/losses from securities in the statement of comprehensive income in the same period in which they arise. Securities are derecognized when the rights to receive cash flows from securities have expired or where the Group has transferred substantially all risks and rewards of ownership.

Transaction costs are costs to acquire financial assets at fair value through profit or loss. They include transfer taxes and duties as well as fees and commissions paid to agents, advisers, brokers and dealers. Transaction costs, when incurred, are immediately recognized as an expense.

Financial liabilities

Financial liabilities are generally classified and subsequently measured at amortized cost using the effective interest method, except for financial liabilities held for trading and derivatives.

Payables to brokers

Payables to brokers result from security transactions and do not bear any interest.

Short-term borrowings from banks

Short-term borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least twelve months after the balance sheet date.

Income taxes

Current income taxes are calculated on the basis of the applicable tax laws in individual countries and recognized as an expense in the period in which the related profits are made.

Assets or liabilities related to current income taxes are reported in the balance sheet in the items «Current tax assets» or «Current tax liabilities». Tax effects arising from temporary differences between the carrying amounts of assets and liabilities in the Group's balance sheet and their corresponding tax values are recognized, respectively, as «Deferred tax assets» and «Deferred tax liabilities». Deferred tax assets arising from temporary differences and from loss carry-forwards eligible for offset are capitalized if it is likely that sufficient taxable profits will be available against which those temporary differences or loss carry-forwards can be offset. Deferred tax assets and deferred tax liabilities are calculated at the tax rates expected to apply in the period in which the tax assets will be realized, or the tax liabilities settled.

Earnings per share

Basic earnings per share are calculated by dividing the net profit/loss attributable to shareholders by the weighted average number of registered shares in issue during the year, less treasury shares. For the diluted earnings per share, the weighted average number of registered shares in issue and the net profit is adjusted to assume conversion of all dilution potential registered shares.

Treasury shares

The company can buy and sell treasury shares in accordance with the Company's article of association, Swiss company law and in compliance with the listing rules of SIX Swiss Exchange.

Treasury shares are recorded as a deduction from the shareholders' equity at the amount of considerations paid («Total cost»). All gains and losses arising from trading in treasury shares are directly credited/debited to retained earnings. The FIFO (first in/first out) method is used for derecognition. The purchase price is booked gross with transaction costs. Treasury shares may be acquired and held by the Company or by other members of the consolidated Group.

Net asset value per share

The net asset value per share is calculated by dividing the shareholders' equity by the number of shares outstanding less treasury shares held at year end.

Dividend income

Dividends on securities are recognized in the income statement when the Group's right to receive payment is established.

Leasing contracts

The Group has two rental contracts for office space in Schaffhausen and Curacao. Due to the immateriality of a right-of-use-asset and a lease liability, no disclosure according to IFRS 16 are made within these consolidated financial statements.

Pension liability

BB Biotech AG maintains for its two employees a defined benefit plan. There is no pension plan for employees of Group companies. Due to the immateriality of any potential pension liability or potential pension asset, no disclosures according to IAS 19 are made within these consolidated financial statements.

Segment reporting

IFRS 8 requires entities to define operating segments and segment performance in the financial statements based on information used by the chief operating decision-maker. The investment manager is considered to be the chief operating decision-maker. An operating segment is a group of assets and operations engaged in providing products or services that are subject to risks and returns that are different from those of other operating segments. The sole operating segment of the Group is investing in companies active in the biotechnology industry. The investment manager works as a team for the entire portfolio, asset allocation is based on a single, integrated investment strategy and the Group's performance is evaluated on an overall basis. Thus the results published in this report correspond to the sole operating segment of investing in companies active in the biotechnology industry.

Related party

Related parties are individuals and companies where the individual or company has the ability, directly or indirectly, to control the other party or to exercise significant influence over the other party in making financial and operating decisions.

Commitments, contingencies and other off-balance sheet transactions

The operations of the Group are affected by legislative, fiscal and regulatory developments for which provisions are made where a legal or constructive obligation has been incurred which will probably lead to an outflow of resources that can be reasonably estimated.

Critical accounting estimates and judgments

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. The Group makes estimates and assumptions that are mainly based on market conditions to value these financial instruments. Since these financial instruments are not traded in an active market, inherent difficulties exist to value these financial instruments. These difficulties cannot be eliminated. The difference between the proceeds from sale of these financial instruments and the carrying amount may be material. [Note 4](#) discloses further details on fair values of financial instruments not traded in active markets.

The Company has assessed whether it is appropriate under IFRS 10 to consolidate the Subsidiaries. IFRS 10 states that an investor controls the investee if, and only if, the investor has all of the following:

- Power over the investee;
- Exposure, or rights, to variable returns from its involvement with the investee; and
- The ability to use its power over the investee to affect the amount of the investor's returns

The Company owns 100% of the capital and voting interest in all four subsidiaries as disclosed in [note 1](#). Therefore the Company has power over the organization and directs the investment activities and dividend policy of its subsidiaries. The scope of the investment management and administration agreement with the investment manager also includes all subsidiaries.

Further, IFRS 10 requires that a subsidiary that provides services related to the parent's investment activities should not be consolidated if the subsidiary itself is an investment entity. The Company also made an assessment as to whether the Company's Subsidiaries meet the definition of an investment entity. IFRS 10 provides that an investment entity should have the following typical characteristics:

- It has more than one investment;
- It has more than one investor;
- It has investors that are not related parties of the entity; and
- It has ownership interests in the form of equity or similar interests.

An investment entity is still required to consolidate its subsidiaries if the subsidiary provides services that relate to the investment entity's investment activities.

The Company concluded that the Subsidiaries do not qualify as investment entities, but are effectively operating subsidiaries as they act as an extension of the Company. They provide requisite investment-related services to the Company and incur costs in doing so, thus the Company consolidates its subsidiaries. Fair value accounting would not have a material impact on the net income and equity of the Group.

3. Financial risk management

Within the framework of the law, articles of incorporation and regulations, the investment manager carries out currency and security forward transactions, buys, sells and makes use of options as well as fulfills all necessary obligations that result from these businesses.

Credit risk

The Group is exposed to credit risk, which is the risk that a counterparty will be unable to pay amount in full when due. The Group measures credit risk and expected credit losses using probability of default, exposure at default and loss given default. The Group considers both historical analysis and forward looking information in determining any expected credit loss.

The Group manages and controls its credit risk by maintaining business relations only with counterparties with an acceptable credit rating. All transactions in securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. The trade will fail if either party fails to meet its obligation. The Group's credit positions, if any, are monitored on a daily basis by the investment manager and are reviewed on a regular basis by the Board of Directors.

As at December 31, 2024 and 2023, the ECL-impairment model did not have a material impact as (i) the majority of the financial assets are measured at fair value through profit or loss and the impairment requirements do not apply to such instruments; and (ii) the financial assets at amortized cost are short-term (no longer than 10 days). As a result, no loss allowance has been recognized.

Market risks

Risk associated with changing market prices

Due to its business activity and the resulting high portion of securities in relation to total assets, the Group is exposed to market price risk arising from uncertainties and fluctuations on the financial and foreign exchange markets.

The Group participates occasionally, but to a substantial extent, in the capital of its investments. In the case of sales of large parts of these investments, it may be able to influence the market price. The Group's securities positions are monitored on a daily basis by the investment manager and are reviewed on a regular basis by the Board of Directors.

The Group's business is to invest in biotechnology companies with the purpose of capital appreciation. Consequently, it is exposed to market risks of this industry. The individual securities are disclosed in [note 4](#) and the valuation is made at fair value. Consequently, any price changes are reflected accordingly by the changes in fair value in the context of the subsequent valuation.

The annual volatility of registered shares BB Biotech AG (reference volatility for the marketable securities) for 2024 is 21.37% (2023: 23.08%). At December 31, 2024, had the value of listed securities increased or decreased by 21.37% (2023: 23.08%) with all other variables held constant, the increase or decrease respectively in net income/loss as well as shareholders' equity would amount to CHF 506.3 mn (2023: CHF 604.7 mn).

At December 31, 2024, the Company holds one investment in unlisted shares (2023: one).

Interest risk

Interest rates on liquid funds are based on market rates. The funds are due on demand.

Short-term borrowings from banks are on current and short-term loan accounts with interest, based at market rates. Due to the high level of own funds, the effect of interest payable on the statement of income is insignificant. The majority of the Group's securities are non-interest bearing; as a result, the Group is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates.

The Group's interest sensitivity is monitored on a daily basis by the investment manager and reviewed on a regular basis by the Board of Directors.

Currency risk

The Group hold assets denominated in currencies other than the Swiss franc, the functional currency. They are therefore exposed to currency risk, as the value of the securities denominated in other currencies will fluctuate due to changes in exchange rates. Depending on the market situation the Group could use foreign currency options and/or forward contracts to reduce the currency risk.

The following table summarizes the Group's exposure to currency risks:

2024	Net exposure 31.12. (in CHF 1 000)	Annual volatility (in %)	Potential impact (in CHF 1 000)¹⁾
USD	2 407 011	7.07	170 176
ANG	84	7.07	6
2023			
USD	2 631 178	7.89	207 600
ANG	122	7.89	10

¹⁾ Potential impact on total comprehensive income as well as shareholders' equity with all other variables held constant

The Group's currency position is monitored on a daily basis by the investment manager and is reviewed on a regular basis by the Board of Directors.

Liquidity risk

The Group invests the majority of its assets in investments that are traded in an active market and can be readily disposed of. The Group's treasury shares, with the exception of shares purchased under a share buy-back program, are considered readily realizable as they are listed on two stock exchanges. The Group can invest a minor part of its portfolio in securities, which are not traded on a stock exchange and may be illiquid. As a result, the Group may not be able to liquidate its investments in these instruments on short notice. In addition, the Group has access to a credit line (notes [5](#) and [13](#)).

The tables below analyze the Group's financial liabilities into relevant maturity groupings based on the period between the balance sheet date and the contractual maturity date (in CHF 1 000):

At December 31, 2024	Less than 1 month	1–3 months	More than 3 months / no stated maturity
Short-term borrowings from banks	117 500	–	–
Other short-term liabilities	2 962	551	–
Total liabilities	120 462	551	–
At December 31, 2023			
Short-term borrowings from banks	304 900	–	–
Payables to brokers	5 436	–	–
Other short-term liabilities	2 800	691	–
Total liabilities	313 136	691	–

The Group's liquidity position is monitored on a daily basis by the investment manager and is reviewed on a regular basis by the Board of Directors.

Diversification

The investment portfolio usually consists of 20 to 35 investments. This includes five to eight large core investments, defined as positions > 5%. Together, these investments will generally account for up to two-thirds of the portfolio. Companies without a stock market listing shall not exceed 10% of the portfolio.

As at December 31, 2024, the Group held eight core investments, representing 68% of the Company's securities (2023: six core investments, 55%). The portfolio is – in line with the strategy – concentrated on a limited number of investments. Risk diversification is therefore limited.

4. Financial assets

Fair values

The following table presents the Group's assets that are measured at fair value through profit and loss at December 31 (in CHF 1 000):

2024	Level 1	Level 2	Level 3	Total
Assets				
Securities				
- Shares	2 369 436	–	37 444	2 406 881
- Derivative instruments	–	–	–	–
Total assets	2 369 436	–	37 444	2 406 881
2023				
Assets				
Securities				
- Shares	2 619 989	–	14 725	2 634 714
- Derivative instruments	–	–	–	–
Total assets	2 619 989	–	14 725	2 634 714

There were no transfers between level 1, 2 and 3 during the reporting period.

The fair value of financial instruments traded in active markets is based on quoted market prices at the balance sheet date. A market is regarded as active if quoted prices are readily and regularly available and those prices represent actual and regularly occurring market transactions on an arm's length basis. The quoted market price used for financial assets held by the Group is the closing price. These instruments are included in level 1.

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available. The options are valued on the basis of the Black-Scholes model which is based on market conditions existing at each balance sheet date. These instruments are included in level 2.

If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. The valuation of level 3 instruments is quarterly reviewed. As soon as new or adjusted parameters are available the valuation of unlisted shares is adjusted accordingly (e.g. earnings multiple model, round of financing). As of December 31, 2024, the Company holds two level 3 instruments (December 31, 2023: two), whereas the value of one is zero.

The table below summarizes the transactions in level 3 instruments (in CHF 1 000):

	2024	2023
Opening balance	14 725	16 179
Purchases	15 139	–
Unrealized gains/(losses) included in gains/losses from securities	7 581	(1 454)
Closing balance	37 444	14 725
Gains/(losses) on level 3 instruments included in gains/losses from securities	7 581	(1 454)

The fair value of level 3 instruments at initial recognition represents the transaction price (purchase of preferred stocks of Rivus Pharmaceuticals in August 2022 for TCHF 16 875 and August 2024 for TCHF 15 139), which was paid in financing rounds together with other investors. For the valuation as at December 31, 2024, it is deemed to be appropriate to use the latest transaction price in USD, as it is a reasonable approximation of fair value at the valuation date given the fact that no events occurred which significantly impact the fair value.

In August 2022, 8 733 538 Radius Health – Contingent Value Rights were allocated from a corporate action. The valuation as of December 31, 2024, is CHF 0 (December 31, 2023: CHF 0).

For assets and liabilities carried at amortized cost, their carrying values are a reasonable approximation of fair value.

Key assumptions for the valuation of the level 3 financial instrument vary from investment to investment. The following table shows the effect on the valuation when these assumptions are changed:

Sensitivity analysis	Fair value	Key assumption	Changes in key assumption	Change in fair value in CHF 1 000
Unlisted shares	37 444	Transaction price	+ 5 percentage points	+ 1872
			- 5 percentage points	- 1872
Contingent Value Rights	0	Net sales target of a drug	Not met	0
			Met	+ 7925

Securities

The changes in value of securities by investment category are as follows (in CHF 1 000):

	Listed shares	Unlisted shares	Derivative instruments	Total
Opening balance as at 01.01.2023 at fair values	3 035 170	16 179	–	3 051 349
Purchases	201 147	–	–	201 147
Sales	(451 169)	–	–	(451 169)
Gains/(losses) from securities	(165 158)	(1 454)	–	(166 613)
<i>Realized gains</i>	28 749	–	–	28 749
<i>Realized losses</i>	(46 543)	–	–	(46 543)
<i>Unrealized gains</i>	276 764	–	–	276 764
<i>Unrealized losses</i>	(424 128)	(1 454)	–	(425 582)
Closing balance as at 31.12.2023 at fair values	2 619 989	14 725	–	2 634 714
Opening balance as at 01.01.2024 at fair values	2 619 989	14 725	–	2 634 714
Purchases	206 303	15 139	316	221 758
Sales	(561 097)	–	(42)	(561 139)
Gains/(losses) from securities	104 241	7 581	(274)	111 548
<i>Realized gains</i>	107 900	–	–	107 900
<i>Realized losses</i>	(46 182)	–	(274)	(46 456)
<i>Unrealized gains</i>	480 172	7 581	–	487 753
<i>Unrealized losses</i>	(437 649)	–	–	(437 649)
Closing balance as at 31.12.2024 at fair values	2 369 436	37 444	–	2 406 881

Securities comprise the following:

Company	Number 31.12.2023	Change	Number 31.12.2024	Market price in original currency 31.12.2024	Valuation CHF mn 31.12.2024	Valuation CHF mn 31.12.2023	
Argenx SE	825 000	(234 000)	591 000	USD	615.00	329.8	264.1
Ionis Pharmaceuticals	8 590 000	(740 000)	7 850 000	USD	34.96	249.0	365.6
Neurocrine Biosciences	2 410 000	(590 000)	1 820 000	USD	136.50	225.4	267.2
Intra-Cellular Therapies	3 040 000	(615 000)	2 425 000	USD	83.52	183.8	183.2
Revolution Medicines	5 046 700	(672 400)	4 374 300	USD	43.74	173.6	121.8
Vertex Pharmaceuticals	640 000	(165 000)	475 000	USD	402.70	173.6	219.1
Alnylam Pharmaceuticals	859 700	(99 700)	760 000	USD	235.31	162.3	138.5
Incyte	2 150 000	–	2 150 000	USD	69.07	134.7	113.6
Agios Pharmaceuticals	4 000 000	(484 850)	3 515 150	USD	32.86	104.8	75.0
Scholar Rock Holding	2 132 725	353 982	2 486 707	USD	43.22	97.5	33.7
Celldex Therapeutics	2 416 296	655 319	3 071 615	USD	25.27	70.4	80.6
Biohaven	1 075 000	965 853	2 040 853	USD	37.35	69.2	38.7
Moderna	1 891 075	(291 075)	1 600 000	USD	41.58	60.4	158.2
Wave Life Sciences	4 494 458	(400 000)	4 094 458	USD	12.37	46.0	19.1
Arvinas	2 494 531	(114 531)	2 380 000	USD	19.17	41.4	86.4
Edgewise Therapeutics	–	1 428 929	1 428 929	USD	26.70	34.6	–
Beam Therapeutics	693 121	825 000	1 518 121	USD	24.80	34.2	15.9
Immunocore	965 654	239 810	1 205 464	USD	29.50	32.3	55.5
Macrogenics	9 929 963	–	9 929 963	USD	3.25	29.3	80.4
Relay Therapeutics	5 925 000	1 450 000	7 375 000	USD	4.12	27.6	54.9
Annexon	–	5 157 290	5 157 290	USD	5.13	24.0	–
Sage Therapeutics	3 505 000	955 693	4 460 693	USD	5.43	22.0	63.9
Esperion Therapeutics	4 194 064	5 750 000	9 944 064	USD	2.20	19.9	10.6
Black Diamond Therapeutics	8 517 839	–	8 517 839	USD	2.14	16.5	20.1
Fate Therapeutics	4 839 779	–	4 839 779	USD	1.65	7.2	15.2
Crispr Therapeutics	880 000	(880 000)	–	USD	n.a.	–	46.4
Essa Pharma	7 879 583	(7 879 583)	–	USD	n.a.	–	43.8
Exelixis	2 000 000	(2 000 000)	–	USD	n.a.	–	40.4
Generation Bio Co.	3 608 280	(3 608 280)	–	USD	n.a.	–	5.0
Molecular Templates	1 029 820	(1 029 820)	–	USD	n.a.	–	3.2
Listed shares						2 369.5	2 620.0
Rivus Pharmaceuticals				USD		37.4	14.7
Unlisted shares						37.4	14.7
Total shares						2 406.9	2 634.7
Molecular Templates – Warrants, 2.4.29	–	769 334	769 334	USD	0.00	0.0	–
Radius Health – Contingent Value Right	8 733 538	–	8 733 538	USD	0.00	0.0	–
Total derivative instruments						–	–
Total securities						2 406.9	2 634.7

Securities are deposited with Bank Julius Baer & Co. Ltd., Zurich.

5. Short-term borrowings from banks

At December 31, 2024, a CHF 117.5 mn short-term loan is outstanding, with interest payable at 0.90% p.a. (2023: CHF 304.9 mn at 2.10% p.a.).

6. Other short-term liabilities

Other short-term liabilities comprise the following:

in CHF 1 000	31.12.2024	31.12.2023
Payables to investment manager	1 892	2 074
Other liabilities	1 621	1 417
Total liabilities to third parties	3 513	3 491

7. Shareholders' equity

The share capital of the Company consists of 55.4 mn fully paid registered shares (2023: 55.4 mn registered shares) with a par value of CHF 0.20 each (2023: CHF 0.20). CHF 2.2 mn of the retained earnings (2023: CHF 2.2 mn) are undistributable.

in CHF 1 000	Share capital	Treasury shares	Retained earnings	Total
Balances at January 1, 2023	11 080	(36 508)	2 711 563	2 686 135
Dividend	–	–	(156 311)	(156 311)
Total comprehensive income for the period	–	–	(206 607)	(206 607)
Balances at December 31, 2023	11 080	(36 508)	2 348 645	2 323 217
Balances at January 1, 2024	11 080	(36 508)	2 348 645	2 323 217
Dividend	–	–	(109 692)	(109 692)
Trade with treasury shares	–	(3 132)	–	(3 132)
Total comprehensive income for the period	–	–	75 899	75 899
Balances at December 31, 2024	11 080	(39 640)	2 314 852	2 286 292

Paid dividend per share 2024: CHF 2.00 (2023: CHF 2.85).

At December 31, 2024 and 2023, the Company has neither authorized nor conditional capital.

Treasury shares

The Company can buy and sell treasury shares in accordance with the Company's articles of association and Swiss company law and in compliance with the listing rules of the SIX Swiss Exchange. During the period from January 1, 2024, to December 31, 2024, the Company has bought 84 000 treasury shares and has not sold any treasury shares (01.01.–31.12.2023: no transactions). As at December 31, 2024, the Company holds 638 000 treasury shares (December 31, 2023: 554 000 shares). The treasury shares as at December 31, 2024, were treated as a deduction from the consolidated shareholders' equity using cost values of TCHF 39 640 (December 31, 2023: TCHF 36 508)

Share buy-back 2nd line (bought for cancellation)

In April 2022, the Board of Directors has approved the repurchase of a maximum of 5 540 000 own registered shares with a nominal value of CHF 0.20 each. The share buy-back program will run from April 13, 2022 until April 11, 2025 at the latest. Until December 31, 2024, 84 000 shares had been repurchased under this share buy-back program (December 31, 2023:

no shares). The repurchase will take place via second trading line for the purpose of a subsequent capital reduction.

8. Administrative expenses

Administrative expenses comprise the following:

in CHF 1 000	2024	2023
Investment manager		
– Management fees	24 943	27 682
Personnel		
– Board of Directors remuneration	1 665	1 680
– Wages and salaries	623	600
– Social insurance contributions and duties	128	120
	27 359	30 083

The remuneration model of BB Biotech AG is determined by the Board of Directors.

Since 2014, the remuneration paid to the investment manager is based upon a 1.1% p.a. all-in fee on the average market capitalization without any additional fixed or performance-based elements of compensation, which is paid on a monthly basis. The compensation of the Board of Directors consists since 2014 of a fixed compensation.

9. Other expenses

Other expenses comprise the following:

in CHF 1 000	2024	2023
Bank charges	492	446
Marketing and financial reporting	995	1 567
Legal and consulting expenses	244	380
Transaction costs	1 082	948
Other expenses	1 134	1 219
	3 947	4 560

10. Income taxes

in CHF 1 000	2024	2023
Operating income before tax	75 953	(206 528)
Expected tax rate (Direct federal, cantonal and communal tax)	14.2%	14.2%
Expected income tax	10 757	(29 286)
Difference between effective local tax rates and the expected Swiss tax rate	10 703	(29 365)
Total income tax	54	79

In the current year, the average effective income tax rate on a consolidated basis was less than 1% (2023: <1%). This low rate is mainly attributable to the fact that a large proportion of operating income was generated by companies located in Curaçao. As at December 31, 2024, there is no nettable loss carry forward (2023: none).

11. Earnings per share

	2024	2023
Total comprehensive profit/(loss) for the period (in CHF 1 000)	75 899	(206 607)
Weighted average number of shares in issue	54 831 538	54 846 000
Earnings per share in CHF	1.38	(3.77)
Income used to determine diluted earnings per share (in CHF 1 000)	75 899	(206 607)
Weighted average number of shares in issue following the dilution	54 831 538	54 846 000
Diluted earnings per share in CHF	1.38	(3.77)

12. Segment reporting

The sole operating segment of the Group reflects the internal management structure and is evaluated on an overall basis. Revenue is derived by investing in a portfolio of companies active in the biotechnology industry for the purpose of capital appreciation. The following results correspond to the sole operating segment of investing in companies active in the biotechnology industry.

The geographical analysis of the profit/(loss) before tax is as follows – all income from financial assets are attributed to a country based on the domiciliation of the issuer of the instrument:

Profit/(loss) before tax in CHF 1 000	2024	2023
Netherlands	159 365	(21 842)
Singapore	29 295	(9 989)
USA	(440)	(191 218)
British Virgin Islands	(4 059)	1 559
Switzerland	(11 354)	8 389
Curaçao	(31 628)	(35 008)
Great Britain	(31 921)	16 181
Canada	(33 305)	25 400
	75 953	(206 528)

13. Assets pledged

At December 31, 2024, the securities in the amount of CHF 2 406.9 mn (2023: CHF 2 634.7 mn) are a collateral for a credit line of CHF 700 mn (2023: CHF 700 mn). At December 31, 2024, a CHF 117.5 mn short-term loan is outstanding (2023: CHF 304.9 mn).

14. Commitments, contingencies and other off-balance sheet transactions

The Group had no commitments or other off-balance sheet transactions open at December 31, 2024 (2023: none).

The operations of the Group are affected by legislative, fiscal and regulatory developments for which provisions are made where deemed necessary. The Board of Directors concludes that as at December 31, 2024, no proceedings existed which could have any material effect on the financial position of the Group (2023: none).

15. Financial instruments by category

Financial assets and liabilities are allocated to categories as follows (in CHF 1 000):

At December 31, 2024	Financial assets at amortized cost	Financial assets at fair value through profit or loss	Total
Assets as per balance sheet			
Cash and cash equivalents	458	–	458
Securities	–	2 406 881	2 406 881
	458	2 406 881	2 407 339
	Financial liabilities at amortized cost	Financial liabilities at fair value through profit or loss	Total
Liabilities as per balance sheet			
Short-term borrowings from banks	117 500	–	117 500
Other short-term liabilities	3 513	–	3 513
	121 013	–	121 013
At December 31, 2023	Financial assets at amortized cost	Financial assets at fair value through profit or loss	Total
Assets as per balance sheet			
Cash and cash equivalents	501	–	501
Receivables from brokers	1 829	–	1 829
Securities	–	2 634 714	2 634 714
	2 330	2 634 714	2 637 044
	Financial liabilities at amortized cost	Financial liabilities at fair value through profit or loss	Total
Liabilities as per balance sheet			
Short-term borrowings from banks	304 900	–	304 900
Payables to brokers	–	5 436	5 436
Other short-term liabilities	3 491	–	3 491
	308 391	5 436	313 827

Profit and loss from financial assets and liabilities are allocated to categories as follows
(in CHF 1 000):

2024	Financial assets at amortized cost	Financial instruments at fair value through profit or loss	Financial liabilities at amortized cost	Total
Profit and loss from financial instruments				
Gains from securities	-	111 548	-	111 548
Interest income	84	-	-	84
Foreign exchange gains	599	-	-	599
Finance expenses	-	-	(4 978)	(4 978)
2023				
Profit and loss from financial instruments				
Interest income	35	-	-	35
Losses from securities	-	(166 613)	-	(166 613)
Foreign exchange gains	490	-	-	490
Finance expenses	-	-	(5 802)	(5 802)

16. Transactions with the investment manager and related party transactions

The investment management and administration of the Company has been delegated to Bellevue Asset Management AG. Based on the 1.1% p.a. all-in fee model, no additional costs incurred at Bellevue Asset Management AG were charged to the BB Biotech Group (2023: none). The amounts outstanding at the balance sheet date are disclosed in [note 6](#), «Other short-term liabilities».

17. Significant shareholders

Based on information received and published by the Company, the following party owns significant voting rights:

Voting rights in %	31.12.2024	31.12.2023
UBS Fund Management AG, Zurich, Switzerland	4.356%	n.a.

18. Subsequent events

There have been no events subsequent to December 31, 2024, until the date of the issue of these consolidated financial statements, which would affect the 2024 consolidated financial statements.

Report on the Audit of the Consolidated Financial Statement

Report of the statutory auditor to the General Meeting of BB Biotech AG, Schaffhausen

Opinion

We have audited the consolidated financial statements of BB Biotech AG (the Company) and its subsidiaries (the Group), which comprise the consolidated balance sheet as at 31 December 2024, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2024 and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with IFRS Accounting Standards and comply with Swiss law.

Basis for Opinion

We conducted our audit in accordance with Swiss law, International Standards on Auditing (ISA) and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the «Auditor's Responsibilities for the Audit of the Consolidated Financial Statements» section of our report. We are independent of the Group in accordance with the provisions of Swiss law, together with the requirements of the Swiss audit profession, as well as those of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter

Valuation of investment securities

The investment portfolio as of 31 December 2024 comprises investments in marketable and non-marketable securities.

We consider this area to be a key audit matter because of the significant value of the securities in the consolidated financial statements.

As set out in [note 4](#) (Schedule of securities) securities amount to CHF 2 407 million or 99.9% of total assets.

The valuation of the securities is prepared by the Investment Manager using the valuation methods disclosed in [note 2](#) (Accounting policies). The Board of Directors approves the valuation of the investment securities.

How our audit addressed the key audit matter

We gained an understanding of the controls in place related to the valuation of investment securities to determine whether the Investment Manager has appropriate controls in place. Further, we verified the adequacy of the applied valuation methods as well as the appropriateness of the resulting valuations.

To audit the valuation of the investment securities we performed the following procedures.

- We compared the valuation methods applied by the Investment Manager with generally accepted valuation methods. Further, we verified the quoted prices of marketable investment securities by comparing them with those from an independent source different from that used by the Investment Manager;
- Additionally, we verified that the valuation of the non-marketable investment securities is in line with the valuation policies of the Group challenging the most important input factors applied in the valuation by comparing them with past figures, benchmarks, publicly available data and our own market assessments.

We obtained sufficient audit evidence to address the risk that the valuation methods were both appropriate and consistently applied by the Investment Manager.

Key audit matter**Ownership of securities**

The securities are safeguarded by an independent custodian.

There is a risk that the Group may not have sufficient legal entitlement to the securities.

We consider this area to be a key audit matter because of the significant value of the securities in the consolidated financial statements.

How our audit addressed the key audit matter

We examined the ownership of the securities by requesting a confirmation of the securities directly from the custodian.

We obtained sufficient audit evidence to address the risk of insufficient legal entitlement to the securities portfolio.

Other Information

The Board of Directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements, the stand-alone financial statements, the remuneration report and our auditor's reports thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Board of Directors' Responsibilities for the Consolidated Financial Statements

The Board of Directors is responsible for the preparation of the consolidated financial statements, which give a true and fair view in accordance with IFRS Accounting Standards and the provisions of Swiss law, and for such internal control as the Board of Directors determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the Board of Directors is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Swiss law, ISA and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate,

they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

A further description of our responsibilities for the audit of the consolidated financial statements is located on EXPERTsuisse's website at: <https://www.expertsuisse.ch/en/audit-report>. This description forms an integral part of our report.

Report on Other Legal and Regulatory Requirements

In accordance with Art. 728a para. 1 item 3 CO and PS-CH 890, we confirm that an internal control system exists, which has been designed for the preparation of the consolidated financial statements according to the instructions of the Board of Directors.

We recommend that the consolidated financial statements submitted to you be approved.

Deloitte AG

Marcel Meyer
Licensed Audit Expert
Auditor in Charge

Mathieu Valette
Licensed Audit Expert

Zurich, 19 February 2025

Balance sheet as at December 31

in CHF	Notes	2024	2023
Current assets			
Cash and cash equivalents		125 695	44 757
Other current receivables		5 022 840	5 992 571
		5 148 535	6 037 328
Non-current assets			
Investments		1 177 069 500	1 177 069 500
		1 177 069 500	1 177 069 500
Total assets		1 182 218 035	1 183 106 828
Current liabilities			
Other current liabilities	2.1	348 387	334 219
Accrued expenses		801 979	467 774
		1 150 366	801 993
Total liabilities		1 150 366	801 993
Shareholders' equity			
Share capital	2.2	11 080 000	11 080 000
Legal capital reserves			
- Paid-in capital reserve ¹⁾		20 579 224	20 579 224
Legal profit reserves			
- General legal reserve		4 500 000	4 500 000
- Reserve for treasury shares ²⁾		39 640 314	36 508 182
Other reserves		187 187 442	190 319 574
Retained earnings	4/5	921 212 821	919 317 855
Treasury shares		(3 132 132)	–
		1 181 067 669	1 182 304 835
Total liabilities and shareholders' equity		1 182 218 035	1 183 106 828

¹⁾ Of which CHF 20 441 000 not confirmed by the Swiss Tax Authorities due to present regulation

²⁾ For treasury shares held by BB Biotech AG and subsidiaries

The financial statements were approved by the Board of Directors of BB Biotech AG on February 18, 2025.

Statement of income for the year ended December 31

in CHF	Notes	2024	2023
Operating income			
Income from investments		111 263 000	156 300 000
Other income	2.3	4 968 669	5 899 016
		116 231 669	162 199 016
Operating expenses			
Administrative expenses	2.4	(2 270 291)	(2 322 459)
Other expenses	2.5	(2 241 885)	(3 036 067)
		(4 512 176)	(5 358 526)
Profit/(loss) before finance income and tax		111 719 493	156 840 490
Finance income		1 182	1 127
Finance expenses		(19 932)	(11 937)
Profit/(loss) before tax		111 700 743	156 829 680
Tax expenses	2.6	(113 776)	(122 808)
Net income for the year		111 586 966	156 706 872

Notes to the financial statements

BB Biotech AG

1. Accounting policies

General

The financial statements of BB Biotech AG (the Company) have been prepared in accordance with the provisions of commercial accounting as set out in the Swiss Code of Obligations. The financial statements have been prepared under the historical cost convention.

Cash and cash equivalents

Cash and cash equivalents includes current accounts at banks. These are stated at the notional amount.

Investments

The investments include the subsidiaries over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Initially and subsequently, investments are valued at historical cost. An impairment is recognized if the value in use is expected to permanently fall below the book value.

Income from investments is recognized in the income statement when the Company's right to receive the dividend payment is established.

Receivables/liabilities

Receivables/liabilities are classified as current assets/liabilities if maturity is expected to be within twelve month after the balance sheet date. Else, they are classified as long-term assets/liabilities. Receivables/liabilities are recognized at notional value. Receivables/liabilities against related parties include transactions with the Board of Directors as well as Group companies and affiliates. Receivables/liabilities against group companies result mainly from cash-pooling activities of the Group. The Group consists of BB Biotech AG and the mentioned subsidiaries under [3.3](#).

Treasury shares

Treasury shares are deducted from shareholders' equity. All profits and losses arising from trading in treasury shares are included in the income statement. A reserve for treasury shares is built for treasury shares held by the Company and its subsidiaries, booked against other reserves. The reserve is based on cost prices.

2. Details and explanations to the financial statements

2.1 Other current liabilities

The other current liabilities comprise the following (in CHF):

	2024	2023
Third parties	311 259	293 658
Investment Manager	37 127	40 561
	348 387	334 219

2.2 Shareholders' equity

The share capital of the Company consists of 55.4 mn fully paid registered shares (2023: 55.4 mn registered shares) with a par value of CHF 0.20 each (2023: CHF 0.20).

In April 2022, the Board of Directors has approved the repurchase of a maximum of 5 540 000 own registered shares with a nominal value of CHF 0.20 each. The share buy-back program will run from April 13, 2022 until April 11, 2025 at the latest. Until December 31, 2024, the Company has bought 84 000 treasury shares under this share buy-back program. The repurchase will take place via second trading line for the purpose of a subsequent capital reduction.

At December 31, 2024 and 2023, the Company has neither authorized nor conditional capital.

2.3 Other income

Other income comprises the following (in CHF):

	2024	2023
Income group services	4 963 000	5 894 000
Other income	5 669	5 016
	4 968 669	5 899 016

2.4 Administrative expenses

Administrative expenses comprise the following (in CHF):

	2024	2023
Board of Directors remuneration	1 665 000	1 680 000
Social insurance contributions and duties	46 111	44 921
Investment manager compensation	453 516	503 308
Staff costs	105 665	94 230
	2 270 291	2 322 459

The remuneration report discloses further details to the Board of Directors compensation.

2.5 Other expenses

Other expenses comprise the following (in CHF):

	2024	2023
Marketing and financial reporting	994 990	1 566 758
Audit, legal and consulting expenses	243 937	380 428
Bank charges	1 107	1 134
Other expenses	1 001 850	1 087 747
	2 241 885	3 036 067

2.6 Tax expenses

Tax expenses comprise the following (in CHF):

	2024	2023
Income taxes	53 644	78 992
Capital taxes	60 132	43 817
	113 776	122 808

3. Other information

3.1 Name, legal form and registered office

BB Biotech AG is a limited company according to the Swiss Code of Obligation and has its registered office at Schwertstrasse 6 in Schaffhausen.

3.2 Declaration of number of full-time equivalents

The number of full-time equivalents did not exceed 10 in the calendar year 2024 (2023: below 10).

3.3 Investments

Investments of BB Biotech AG comprise, in the business years 2024 and 2023, the following subsidiaries:

Company	Capital in CHF 1 000	Capital and voting interest in %
Biotech Focus N.V., Curaçao	11	100
Biotech Growth N.V., Curaçao	11	100
Biotech Invest N.V., Curaçao	11	100
Biotech Target N.V., Curaçao	11	100

3.4 Treasury shares (balances and change)

Treasury shares are held directly by BB Biotech AG and indirectly by its 100% subsidiary Biotech Target N.V.

	BB Biotech AG	Biotech Target N.V.	Total
Balance at January 1, 2023	–	554 000	554 000
Balance at December 31, 2023	–	554 000	554 000
Balance at January 1, 2024	–	554 000	554 000
Purchase of shares at an average price of CHF 37.29	84 000	–	84 000
Balance at December 31, 2024	84 000	554 000	638 000

3.5 Audit fees

The audit fees comprise the following (in CHF):

	2024	2023
Audit fees	120 000	120 000
Audit-related fees	5 000	–
ESG training of the Board of Directors	–	18 000
	125 000	138 000

3.6 Commitments and contingencies

The Company had no commitments or other off-balance sheet transactions open at December 31, 2024 (2023: none).

The operations of the Company are affected by legislative, fiscal and regulatory developments for which provisions are made where deemed necessary. The Board of Directors concludes that as at December 31, 2024, no proceedings existed which could have any material effect on the financial position of the Company (2023: none).

3.7 Subsequent events

There have been no events subsequent to December 31, 2024, which would affect the 2024 financial statements.

3.8 Significant shareholders

Based on information received and published by the Company, the following party owns significant voting rights:

Voting rights in %	31.12.2024	31.12.2023
UBS Fund Management AG, Zurich, Switzerland	4.356%	n.a.

3.9 Statement of holdings of the Board of Directors

As at December 31, the Board of Directors held the following registered shares of BB Biotech AG:

	2024	2023
Dr. Thomas von Planta, Chairman	18 888	12 000
Dr. Clive Meanwell, Vice-Chairman	5 163	5 163
Laura Hamill	–	–
Dr. Pearl Huang	–	–
Prof. Dr. Mads Krogsgaard Thomsen	17 750	–
Camilla Soenderby	–	–
Dr. Erich Hunziker (until March 2024)	n.a.	957 884

3.10 Management contracts

On behalf of the Company, the Board of Directors has entered into a management contract with Bellevue Asset Management AG (investment manager and administrator). In this contract, the investment manager commits to carry out management services relating to the investment activity and general management of BB Biotech AG. Under this contract the Company paid in the business year 2024 CHF 453 516 (2023: CHF 503 308) to Bellevue Asset Management AG.

3.11 Management report and cash flow statement

Due to the fact that BB Biotech AG prepares consolidated financial statements in accordance with a recognized international accounting standard (IFRS), the Company doesn't prepare, in line with the legal requirements, a management report and cash flow statement.

4. Movements on retained earnings

in CHF	2024	2023
Retained earnings at the beginning of the year	919 317 855	918 922 082
Dividend	(109 692 000)	(156 311 100)
Net income for the year	111 586 966	156 706 872
Retained earnings at the end of the year	921 212 821	919 317 855

5. Proposal of the Board of Directors for the appropriation of retained earnings

in CHF	2024 Proposal of the Board	2023 Resolution passed at the AGM
Retained earnings at the disposal of the Annual General Meeting	921 212 821	919 317 855
Dividend (per share 2024: CHF 1.80; 2023: CHF 2.00)	(99 720 000)	(109 692 000)
Carry forward to the next period	821 492 821	809 625 855
	921 212 821	919 317 855

Report on the Audit of the Financial Statements

Report of the statutory Auditor to the General Meeting of BB Biotech AG, Schaffhausen

Opinion

We have audited the financial statements of BB Biotech AG (the Company), which comprise the balance sheet as at 31 December 2024, the statement of income for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements comply with Swiss law and the Company's articles of incorporation.

Basis for Opinion

We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the «Auditor's Responsibilities for the Audit of the Financial Statements» section of our report. We are independent of the Company in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. We have determined that there are no key audit matters to be communicated in our report.

Other information

The Board of Directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements, the stand-alone financial statements, the remuneration report and our auditor's reports thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Board of Directors' Responsibilities for the Financial Statements

The Board of Directors is responsible for the preparation of the financial statements in accordance with the provisions of Swiss law and the Company's articles of incorporation, and for such internal control as the Board of Directors determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Swiss law and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on EXPERTsuisse's website at: <https://www.expertsuisse.ch/en/audit-report>. This description forms an integral part of our report.

Report on Other Legal and Regulatory Requirements

In accordance with Art. 728a para. 1 item 3 CO and PS-CH 890, we confirm that an internal control system exists, which has been designed for the preparation of the financial statements according to the instructions of the Board of Directors.

Based on our audit in accordance with Art. 728a para. 1 item 2 CO, we confirm that the proposal of the Board of Directors complies with Swiss law and the Company's articles of incorporation. We recommend that the financial statements submitted to you be approved.

Deloitte AG

Marcel Meyer
Licensed Audit Expert
Auditor in Charge

Mathieu Valette
Licensed Audit Expert

Zurich, February 19, 2025